Glenmark Pharmaceuticals’ shares surged following its subsidiary’s $700 million upfront payment from AbbVie for an exclusive licensing agreement concerning IGI’s lead drug candidate, ISB 2001. The deal grants AbbVie rights in key markets, while Glenmark retains commercialization in emerging regions.
Originally published by The Economic Times https://economictimes.indiatimes.com/markets